Objective and subjective measures of dalfampridine efficacy in clinical practice
Background Multiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and investigated response using timed 25 foot walk (T25FW) improvement and a patien...
Gardado en:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publishing
2018-07-01
|
| Series: | Multiple Sclerosis Journal - Experimental, Translational and Clinical |
| Acceso en liña: | https://doi.org/10.1177/2055217318786742 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|